Advertisement
Canada markets closed

  • S&P/TSX

    24,822.54
    +132.06 (+0.53%)
     

  • S&P 500

    5,864.67
    +23.20 (+0.40%)
     

  • DOW

    43,275.91
    +36.86 (+0.09%)
     

  • CAD/USD

    0.7246
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    69.34
    -1.33 (-1.88%)
     

  • Bitcoin CAD

    94,185.89
    -508.91 (-0.54%)
     

  • XRP CAD

    0.75
    -0.00 (-0.64%)
     

  • GOLD FUTURES

    2,736.40
    +28.90 (+1.07%)
     

  • RUSSELL 2000

    2,276.09
    -4.76 (-0.21%)
     

  • 10-Yr Bond

    4.0730
    -0.0230 (-0.56%)
     

  • NASDAQ

    18,489.55
    +115.94 (+0.63%)
     

  • VOLATILITY

    18.03
    -1.08 (-5.65%)
     

  • FTSE

    8,358.25
    -26.88 (-0.32%)
     

  • NIKKEI 225

    38,981.75
    +70.56 (+0.18%)
     

  • CAD/EUR

    0.6666
    -0.0024 (-0.36%)
     

NeoGenomics: Q2 Earnings Snapshot

Associated Press Finance
·1 min read

FORT MYERS, Fla. (AP) — FORT MYERS, Fla. (AP) — NeoGenomics Inc. (NEO) on Monday reported a loss of $18.6 million in its second quarter.

On a per-share basis, the Fort Myers, Florida-based company said it had a loss of 15 cents. Earnings, adjusted for stock option expense and amortization costs, came to 3 cents per share.

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was breakeven on a per-share basis.

The operator of cancer-focused testing laboratories posted revenue of $164.5 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $162.1 million.

NeoGenomics expects full-year revenue in the range of $655 million to $667 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NEO at https://www.zacks.com/ap/NEO